113 related articles for article (PubMed ID: 16670289)
1. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model.
van Vuuren AJ; van Roon JA; Walraven V; Stuij I; Harmsen MC; McLaughlin PM; van de Winkel JG; Thepen T
J Immunol; 2006 May; 176(10):5833-8. PubMed ID: 16670289
[TBL] [Abstract][Full Text] [Related]
2. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin.
van Roon JA; van Vuuren AJ; Wijngaarden S; Jacobs KM; Bijlsma JW; Lafeber FP; Thepen T; van de Winkel JG
Arthritis Rheum; 2003 May; 48(5):1229-38. PubMed ID: 12746896
[TBL] [Abstract][Full Text] [Related]
3. Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate.
van Roon JA; Bijlsma JW; van de Winkel JG; Lafeber FP
Ann Rheum Dis; 2005 Jun; 64(6):865-70. PubMed ID: 15539412
[TBL] [Abstract][Full Text] [Related]
4. Resolution of cutaneous inflammation after local elimination of macrophages.
Thepen T; van Vuuren AJ; Kiekens RC; Damen CA; Vooijs WC; van De Winkel JG
Nat Biotechnol; 2000 Jan; 18(1):48-51. PubMed ID: 10625390
[TBL] [Abstract][Full Text] [Related]
5. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.
Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S
Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788
[TBL] [Abstract][Full Text] [Related]
6. Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats.
Cascão R; Vidal B; Lopes IP; Paisana E; Rino J; Moita LF; Fonseca JE
PLoS One; 2015; 10(12):e0142448. PubMed ID: 26658436
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an immunotoxin to folate receptor beta in the intra-articular treatment of antigen-induced arthritis.
Nagai T; Kyo A; Hasui K; Takao S; Matsuyama T
Arthritis Res Ther; 2012 May; 14(3):R106. PubMed ID: 22551402
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis.
Krausz S; Garcia S; Ambarus CA; de Launay D; Foster M; Naiman B; Iverson W; Connor JR; Sleeman MA; Coyle AJ; Hamann J; Baeten D; Tak PP; Reedquist KA
Ann Rheum Dis; 2012 Aug; 71(8):1402-10. PubMed ID: 22730375
[TBL] [Abstract][Full Text] [Related]
9. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
[TBL] [Abstract][Full Text] [Related]
11. Withaferin-A, a steroidal lactone encapsulated mannose decorated liposomes ameliorates rheumatoid arthritis by intriguing the macrophage repolarization in adjuvant-induced arthritic rats.
Sultana F; Neog MK; Rasool M
Colloids Surf B Biointerfaces; 2017 Jul; 155():349-365. PubMed ID: 28454064
[TBL] [Abstract][Full Text] [Related]
12. SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis.
Put S; Schoonooghe S; Devoogdt N; Schurgers E; Avau A; Mitera T; D'Huyvetter M; De Baetselier P; Raes G; Lahoutte T; Matthys P
J Nucl Med; 2013 May; 54(5):807-14. PubMed ID: 23447654
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.
Hristodorov D; Mladenov R; von Felbert V; Huhn M; Fischer R; Barth S; Thepen T
MAbs; 2015; 7(5):853-62. PubMed ID: 26218624
[TBL] [Abstract][Full Text] [Related]
14. CD64 as novel molecular imaging marker for the characterization of synovitis in rheumatoid arthritis.
Theeuwes WF; Di Ceglie I; Dorst DN; Blom AB; Bos DL; Vogl T; Tas SW; Jimenez-Royo P; Bergstrom M; Cleveland M; van der Kraan PM; Laverman P; Koenders MI; van Lent PL; van den Bosch MHJ
Arthritis Res Ther; 2023 Aug; 25(1):158. PubMed ID: 37653557
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-15 receptor-directed immunotoxins atteunuate disease severity in rat adjuvant arthritis.
Wang D; Deng X; Leng X; Mao X
Mol Immunol; 2010 Apr; 47(7-8):1535-43. PubMed ID: 20188418
[TBL] [Abstract][Full Text] [Related]
17. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.
Hristodorov D; Mladenov R; Huhn M; Barth S; Thepen T
Toxins (Basel); 2012 Sep; 4(9):676-94. PubMed ID: 23105975
[TBL] [Abstract][Full Text] [Related]
18. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis.
Ruth JH; Volin MV; Haines GK; Woodruff DC; Katschke KJ; Woods JM; Park CC; Morel JC; Koch AE
Arthritis Rheum; 2001 Jul; 44(7):1568-81. PubMed ID: 11465708
[TBL] [Abstract][Full Text] [Related]
19. Fcgamma receptor 1 (CD64), a target beyond cancer.
Thepen T; Huhn M; Melmer G; Tur MK; Barth S
Curr Pharm Des; 2009; 15(23):2712-8. PubMed ID: 19689341
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.
Chao CC; Chen SJ; Adamopoulos IE; Davis N; Hong K; Vu A; Kwan S; Fayadat-Dilman L; Asio A; Bowman EP
Autoimmunity; 2011 May; 44(3):243-52. PubMed ID: 20925596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
